Hangzhou Tigermed Consulting Co., Ltd. Class A

As of June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H carries a market capitalization of 43.77B, placing it among publicly traded companies globally. Its enterprise value stands at 48.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hangzhou Tigermed Consulting Co., Ltd. Class H's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H has 1.26B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.89, and the price-to-book ratio stands at 1.94.

As of June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H trades at an EV/EBITDA multiple of 27,522.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27,522.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 48.20B versus a market cap of 43.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H posted a negative return on equity (ROE) of -1.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.16, reflecting losses generated across the asset base. The company generates approximately 763,972.69 in revenue per employee across its workforce of 10,893.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 103.14 indicates how many times Hangzhou Tigermed Consulting Co., Ltd. Class H sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H recorded 252.57M in income tax expense. The company reported a pretax loss of -828,636.60 and -378.91M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H's stock has declined approximately 7.91% over the past 52 weeks. The 50-day moving average sits at 42.41, while the 200-day moving average is 41.44.

Over the twelve months ended June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H generated 8.32B in revenue and converted that into -378.91M in net income, yielding earnings per share of -0.27. EBITDA reached 1.75M, while operating income came in at 845.61M.

As of June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H holds 2.46B in cash and equivalents against 2.71B in total debt, resulting in a net debt position of -261.86M. Total book value stands at 22.51B, with working capital of 4.56B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H posted a gross margin of 26.89, reflecting its pricing power and cost economics. The operating margin of 10.16 and net profit margin of -4.55 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H paid dividends of 0.35 per share. The dividend payout ratio of -258.57 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.89, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hangzhou Tigermed Consulting Co., Ltd. Class H shareholders.

As of June 30, 2026, Hangzhou Tigermed Consulting Co., Ltd. Class H has an Altman Z-Score of 5.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.